胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征的临床效果观察

Observation on the clinical efficacy of thymosin alpha-1 adjuvant therapy in the treatment of asthma COPD overlap syndrome

目的:分析胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征的临床效果。方法:收治哮喘-慢阻肺重叠综合征患者70例,均分两组。接受常规治疗患者为参照组,接受胸腺肽α-1辅助治疗的为研究组,对两组治疗效果进行统计和总结。结果:治疗后,研究组PaO_2、FEV_1、FEV_1/FVC明显优于参照组;研究组CD3^+、CD4^+和CD8^+等指标也明显优于参照组,差异均有统计学意义(P<0.05)。结论:哮喘-慢阻肺重叠综合征予以胸腺肽α-1辅助治疗,不仅可以使患者的免疫功能得以增强,其自身肺功能也可得以改善。

Objective:To analyze the clinical efficacy of thymosin alpha-1 adjuvant therapy in the treatment of asthma COPD overlap syndrome.Methods:70 patients with asthma COPD overlap syndrome were selected.They were divided into the two groups on average.Patients received conventional treatment were selected as the reference group,while patients received thymosin alpha-1 adjuvant the rapy were selected as the study group.The treatment effect of the two groups of patients were statistically summarized.Results:After treatment,PaO_2,FEV_1 and FEV_1/FVC in the study group were significantly better than those in the reference group.The indexes of CD3^+,CD4^+and CD8^+in the study group were obviously better than those of the reference group.The differences were statistically significant(P<0.05).Conclusion:The treatment of asthma COPD overlap syndrome by thymosin alpha-1 adjuvant therapy can not only improve the immune function of patients,but also improve the lung function.